Sarah Foster Adams

Sarah Foster Adams

Auto-generated profile, based on publicly available information

Sarah Foster Adams

Division of Gynecologic Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
MSMara P. Steinkamp
Mara P. Steinkamp
ILIrina Lagutina
Irina Lagutina
KBKathryn J. Brayer
Kathryn J. Brayer
FSFred Schultz
Fred Schultz
DBDanielle Burke
Danielle Burke
Angela Wandinger-NessAngela Wandinger-Ness
Angela Wandinger-Ness
The importance of the immune microenvironment in ovarian cancer progression, metastasis, and response to therapies has become increasingly clear, especially with the new emphasis on immunotherapies. To leverage the power of patient-derived xenograft (PDX) models within a humanized immune microenvironment, three ovarian cancer PDXs were grown in humanized NBSGW (huNBSGW) mice engrafted with human CD34+ cord blood–derived hematopoietic stem cells. Analysis of cytokine levels in the ascites fluid and identification of infiltrating immune cells in the tumors demonstrated that these humanized PDX (huPDX) established an immune tumor microenvironment similar to what has been reported for patients with ovarian cancer. The lack of human myeloid cell differentiation has been a major setback for humanized mouse models, but our analysis shows that PDX engraftment increases the human myeloid population in the peripheral blood. Analysis of cytokines within the ascites fluid of huPDX revealed high levels of human M-CSF, a key myeloid differentiation factor as well as other elevated cytokines that have previously been identified in ovarian cancer patient ascites fluid including those involved in immune cell differentiation and recruitment. Human tumor-associated macrophages and tumor-infiltrating lymphocytes were detected within the tumors of humanized mice, demonstrating immune cell recruitment to tumors. Comparison of the three huPDX revealed certain differences in cytokine signatures and in the extent of immune cell recruitment. Our studies show that huNBSGW PDX models reconstitute important aspects of the ovarian cancer immune tumor microenvironment, which may recommend these models for preclinical therapeutic trials. Significance: huPDX models are ideal preclinical models for testing novel therapies. They reflect the genetic heterogeneity of the patient population, enhance human myeloid differentiation, and recruit immune cells to the tumor microenvironment.

13 April 2026 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
FBFrances R. Balkwill
Frances R. Balkwill
CLCéline M. Laumont
Céline M. Laumont
NBNikki Burdett
Nikki Burdett
OSOlivia Le Saux
Olivia Le Saux
DGDale W. Garsed
Dale W. Garsed
DBDavid D. Bowtell
David D. Bowtell

1 October 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JLJamie L. Lesnock
Jamie L. Lesnock
STSarah Temin
Sarah Temin
SBSara Bouberhan
Sara Bouberhan
SASarah F. Adams
Sarah F. Adams
EBEmma L. Barber
Emma L. Barber
JSJennifer M. Scalici
Jennifer M. Scalici
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. PURPOSE: To provide guidance regarding the systemic treatment of patients with high-grade serous and/or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) experiencing recurrence. METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Eight hundred nineteen publications were identified in the literature search. After applying the eligibility criteria, 147 publications of randomized controlled trials and systematic reviews comprising the entire body of evidence remained, forming the evidentiary basis, of which 36 directly informed the guideline recommendations. RECOMMENDATIONS: For patients with recurrent platinum-sensitive EOC, clinicians should offer platinum-based combination regimens, specifically pegylated liposomal doxorubicin (PLD) plus carboplatin, paclitaxel plus carboplatin, or gemcitabine plus carboplatin. Bevacizumab may be added to a platinum-based doublet followed by bevacizumab maintenance. For patients who are not candidates for platinum-based therapy, clinicians may utilize recommendations for first-line treatment of patients with relapsed platinum-resistant disease. For patients with platinum-resistant or platinum-refractory EOC high-grade disease and validated folate receptor alpha (FRα) expression, mirvetuximab soravtansine is strongly recommended. Other recommended systemic options for this population include PLD monotherapy, paclitaxel (once weekly or once every 3 weeks), bevacizumab in combination with chemotherapy, or the combination of relacorilant and nab-paclitaxel; gemcitabine monotherapy remains a conditional alternative. Regarding surgical interventions, there is currently insufficient evidence to recommend secondary cytoreduction or hyperthermic intraperitoneal chemotherapy. Clinicians may discuss secondary cytoreduction for platinum-sensitive recurrences where complete gross resection is highly achievable. Post-treatment monitoring and specialty survivorship care should be offered on a case-by-case basis, potentially including physical exams, biochemical testing, and imaging. There is insufficient data to recommend one combination versus another. Additional information is available on the ASCO Publications website . Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in the Appendix (online only) for more .

4 April 2023
Verified
Other
Open access
MSMara P. Steinkamp
Mara P. Steinkamp
ILIrina Lagutina
Irina Lagutina
KBKathryn J. Brayer
Kathryn J. Brayer
FSFred Schultz
Fred Schultz
DBDanielle Burke
Danielle Burke
Angela Wandinger-NessAngela Wandinger-Ness
Angela Wandinger-Ness
Levels of human factors in the plasma of a non-tumor bearing humanized NBSGW and a non-humanized non-tumor bearing NBSGW control.

4 April 2023
Verified
Other
Open access
MSMara P. Steinkamp
Mara P. Steinkamp
ILIrina Lagutina
Irina Lagutina
KBKathryn J. Brayer
Kathryn J. Brayer
FSFred Schultz
Fred Schultz
DBDanielle Burke
Danielle Burke
Angela Wandinger-NessAngela Wandinger-Ness
Angela Wandinger-Ness
Levels of human M-CSF detected in patient ascites fluid

6 May 2024
Verified
Other
Open access
MSMara P. Steinkamp
Mara P. Steinkamp
ILIrina Lagutina
Irina Lagutina
KBKathryn J. Brayer
Kathryn J. Brayer
FSFred Schultz
Fred Schultz
DBDanielle Burke
Danielle Burke
Angela Wandinger-NessAngela Wandinger-Ness
Angela Wandinger-Ness
The importance of the immune microenvironment in ovarian cancer progression, metastasis, and response to therapies has become increasingly clear, especially with the new emphasis on immunotherapies. To leverage the power of patient-derived xenograft (PDX) models within a humanized immune microenvironment, three ovarian cancer PDXs were grown in humanized NBSGW (huNBSGW) mice engrafted with human CD34+ cord blood–derived hematopoietic stem cells. Analysis of cytokine levels in the ascites fluid and identification of infiltrating immune cells in the tumors demonstrated that these humanized PDX (huPDX) established an immune tumor microenvironment similar to what has been reported for patients with ovarian cancer. The lack of human myeloid cell differentiation has been a major setback for humanized mouse models, but our analysis shows that PDX engraftment increases the human myeloid population in the peripheral blood. Analysis of cytokines within the ascites fluid of huPDX revealed high levels of human M-CSF, a key myeloid differentiation factor as well as other elevated cytokines that have previously been identified in ovarian cancer patient ascites fluid including those involved in immune cell differentiation and recruitment. Human tumor-associated macrophages and tumor-infiltrating lymphocytes were detected within the tumors of humanized mice, demonstrating immune cell recruitment to tumors. Comparison of the three huPDX revealed certain differences in cytokine signatures and in the extent of immune cell recruitment. Our studies show that huNBSGW PDX models reconstitute important aspects of the ovarian cancer immune tumor microenvironment, which may recommend these models for preclinical therapeutic trials.Significance:huPDX models are ideal preclinical models for testing novel therapies. They reflect the genetic heterogeneity of the patient population, enhance human myeloid differentiation, and recruit immune cells to the tumor microenvironment.